📊 PGNY Key Takeaways
Is Progyny, Inc. (PGNY) a Good Investment?
Progyny demonstrates exceptional cash generation ($191.8M FCF, 14.9% FCF margin) and pristine financial health with zero debt and $112.2M cash, providing substantial operational flexibility. However, flat net income growth (+0.0% YoY) despite 10.4% revenue growth indicates margin compression and rising operating expenses that offset top-line gains, warranting monitoring before a stronger conviction.
Why Buy Progyny, Inc. Stock? PGNY Key Strengths
- Outstanding free cash flow generation of $191.8M (14.9% of revenue) with low capex requirements
- Pristine balance sheet with zero debt, $112.2M cash, and 2.73x current ratio providing strong financial flexibility
- Solid revenue growth of 10.4% YoY in essential healthcare services sector with recurring revenue characteristics
- EPS growth of 14.0% YoY driven by disciplined capital allocation through share repurchases
PGNY Stock Risks: Progyny, Inc. Investment Risks
- Flat net income growth (+0.0% YoY) despite 10.4% revenue expansion indicates margin compression and operating expense acceleration outpacing sales
- Thin profitability margins (4.5% net margin, 6.6% operating margin) with limited cushion for adverse business conditions
- Modest returns on capital (11.3% ROE, 7.9% ROA) suggest limited pricing power or rising cost pressures in competitive healthcare market
- Operating leverage not materializing - fixed costs not being absorbed by incremental revenue growth
Key Metrics to Watch
- Operating expense ratio trend and operating margin expansion/contraction
- Gross margin stability and unit economics in core fertility services
- Free cash flow sustainability and cash conversion rate relative to earnings
- Operating leverage as revenue scales and path to net income re-acceleration
Progyny, Inc. (PGNY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.73x current ratio provides a solid financial cushion.
PGNY Profit Margin, ROE & Profitability Analysis
PGNY vs Services Sector: How Progyny, Inc. Compares
How Progyny, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Progyny, Inc. Stock Overvalued? PGNY Valuation Analysis 2026
Based on fundamental analysis, Progyny, Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Progyny, Inc. Balance Sheet: PGNY Debt, Cash & Liquidity
PGNY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Progyny, Inc.'s revenue has grown significantly by 64% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.62 reflects profitable operations.
PGNY Revenue Growth, EPS Growth & YoY Performance
PGNY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $286.6M | $10.4M | $0.11 |
| Q2 2025 | $304.1M | $16.5M | $0.17 |
| Q1 2025 | $278.1M | $15.1M | $0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Progyny, Inc. Dividends, Buybacks & Capital Allocation
PGNY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Progyny, Inc. (CIK: 0001551306)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PGNY
What is the AI rating for PGNY?
Progyny, Inc. (PGNY) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PGNY's key strengths?
Claude: Outstanding free cash flow generation of $191.8M (14.9% of revenue) with low capex requirements. Pristine balance sheet with zero debt, $112.2M cash, and 2.73x current ratio providing strong financial flexibility.
What are the risks of investing in PGNY?
Claude: Flat net income growth (+0.0% YoY) despite 10.4% revenue expansion indicates margin compression and operating expense acceleration outpacing sales. Thin profitability margins (4.5% net margin, 6.6% operating margin) with limited cushion for adverse business conditions.
What is PGNY's revenue and growth?
Progyny, Inc. reported revenue of $1.3B.
Does PGNY pay dividends?
Progyny, Inc. does not currently pay dividends.
Where can I find PGNY SEC filings?
Official SEC filings for Progyny, Inc. (CIK: 0001551306) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PGNY's EPS?
Progyny, Inc. has a diluted EPS of $0.65.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PGNY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Progyny, Inc. has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is PGNY stock overvalued or undervalued?
Valuation metrics for PGNY: ROE of 11.3% (sector avg: 16%), net margin of 4.5% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy PGNY stock in 2026?
Our dual AI analysis gives Progyny, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PGNY's free cash flow?
Progyny, Inc.'s operating cash flow is $210.2M, with capital expenditures of $18.4M. FCF margin is 14.9%.
How does PGNY compare to other Services stocks?
Vs Services sector averages: Net margin 4.5% (avg: 10%), ROE 11.3% (avg: 16%), current ratio 2.73 (avg: 1.5).